KYOTO, JAPAN, Aug 14, 2024 – (JCN Newswire via SeaPRwire.com) – Valuufy, a pioneering fintech startup drawn from a decades’ work in measuring and creating sustainable value at Doshisha University’s Value Research Center, has launched with its groundbreaking ValuuCompass, a comprehensive framework set to transform sustainable business practices and sustainability investing by providing a fully […]
(SeaPRwire) – 億萬富翁在與前美國總統唐納·川普長時間交談後發出了邀請 伊隆·馬斯克提議在 X Spaces 平台上採訪美國副總統兼民主黨總統候選人卡瑪拉·賀里斯。這位億萬富翁是在週一與前美國總統唐納·川普長時間交談後發出邀請的。 與川普的採訪持續了約兩個小時，川普競選團隊稱之為「世紀採訪」…
TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI […]
Development Highlights – During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs. – In the first half of […]
重點成果 – 期內，集團共有4個創新產品獲中國國家藥品監督管理局（「NMPA」）批准上市，分別為安得衛（貝莫蘇拜單抗注射液）、安柏尼（富馬酸安奈克替尼膠囊）、安洛晴（枸櫞酸依奉阿克膠囊）和貝樂林（利拉魯肽注射液），其中3個為國家1類創新藥。 – 2024年上半年，集團創新產品收入達到61.3億元…